![]() | |
Clinical data | |
---|---|
Other names | Nexus |
Routes of administration | Oral, insufflation, rectal |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | liver |
Onset of action | 20–40 min. (Oral) |
Elimination half-life | 2.48 ± 3.20 h[1] |
Duration of action | 4–12 hours depending on route of administration |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.164.088 |
Chemical and physical data | |
Formula | C10H14BrNO2 |
Molar mass | 260.131 g·mol−1 |
3D model (JSmol) | |
| |
|
2C-B (4-bromo-2,5-dimethoxyphenethylamine), also known as Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug.[2] The substance was first synthesized by Alexander Shulgin in 1974, and gained an initial reputation for potential psychotherapeutic use, but its use has been limited to mainly recreational use. To date, there is limited scientific information regarding the drug's pharmacokinetics and pharmacological effects in humans. The existing studies primarily classify 2C-B as a stimulant and hallucinogen, and less commonly an entactogen and empathogen.[3]
2C-B, also referred to by a number of slang names, is known to circulate in the illicit market in multiple forms:[4][5] as a powder, in capsules or pills. For recreational use, the substance is generally consumed orally or nasally. In Shulgin's book PiHKAL, the oral dosage range is listed as 12–24 mg.[6]